Diagnosis and Prediction of Relapses in Susac Syndrome: A New Use for MR Postcontrast FLAIR Leptomeningeal Enhancement

REFERENCES

1. 1.↵
   2. Susac JO,
   3. Hardman JM,
   4. Selhorst JB

   . Microangiopathy of the brain and retina. Neurology 1979;29:313–16 doi:10.1212/WNL.29.3.313 pmid:571975

   Abstract/FREE Full Text
2. 2.↵
   2. Susac JO

   . Susac's syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 1994;44:591–93 doi:10.1212/WNL.44.4.591 pmid:8164809

   FREE Full Text
3. 3.↵
   2. Papo T,
   3. Biousse V,
   4. Lehoang P, et al

   . Susac syndrome. Medicine (Baltimore) 1998;77:3–11 doi:10.1097/00005792-199801000-00002 pmid:9465860

   CrossRefPubMed
4. 4.↵
   2. Kleffner I,
   3. Dörr J,
   4. Ringelstein M, et al

   ; European Susac Consortium (EuSaC). Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry 2016;87:1287–95 doi:10.1136/jnnp-2016-314295 pmid:28103199

   Abstract/FREE Full Text
5. 5.↵
   2. Dörr J,
   3. Krautwald S,
   4. Wildemann B, et al

   . Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol 2013;9:307–16 doi:10.1038/nrneurol.2013.82 pmid:23628737

   CrossRefPubMed
6. 6.↵
   2. Buzzard KA,
   3. Reddel SW,
   4. Yiannikas C, et al

   . Distinguishing Susac's syndrome from multiple sclerosis. J Neurol 2015;262:1613–21 doi:10.1007/s00415-014-7628-9 pmid:25547511

   CrossRefPubMed
7. 7.↵
   2. Sarbu N,
   3. Shih RY,
   4. Jones RV, et al

   . White matter diseases with radiologic-pathologic correlation. Radiographics 2016;36:1426–47 doi:10.1148/rg.2016160031 pmid:27618323

   CrossRefPubMed
8. 8.↵
   2. Seifert-Held T,
   3. Langner-Wegscheider BJ,
   4. Komposch M, et al

   . Susac's syndrome: clinical course and epidemiology in a Central European population. Int J Neurosci 2017;127:776–780 doi:10.1080/00207454.2016.1254631 pmid:27788613

   CrossRefPubMed
9. 9.↵
   2. Zurawski J,
   3. Lassmann H,
   4. Bakshi R

   . Use of magnetic resonance imaging to visualize leptomeningeal inflammation in patients with multiple sclerosis: a review. JAMA Neurol 2017;74:100–09 doi:10.1001/jamaneurol.2016.4237 pmid:27893883

   CrossRefPubMed
10. 10.↵
    2. Susac JO,
    3. Murtagh FR,
    4. Egan RA, et al

    . MRI findings in Susac's syndrome. Neurology 2003;61:1783–87 doi:10.1212/01.WNL.0000103880.29693.48 pmid:14694047

    Abstract/FREE Full Text
11. 11.↵
    2. Sastre-Garriga J

    . Leptomeningeal enhancement in Susac's syndrome and multiple sclerosis: time to expect the unexpected? Mult Scler 2016;22:975–76 doi:10.1177/1352458516644677 pmid:27207451

    CrossRefPubMed
12. 12.↵
    2. Engisch R,
    3. Titelbaum DS,
    4. Chilver-Stainer L, et al

    . Susac's syndrome: leptomeningeal enhancement on 3D FLAIR MRI. Mult Scler 2016;22:972–74 doi:10.1177/1352458516636836 pmid:27207452

    CrossRefPubMed
13. 13.↵
    2. Fazekas F,
    3. Chawluk JB,
    4. Alavi A, et al

    . MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 1987;149:351–56 doi:10.2214/ajr.149.2.351 pmid:3496763

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Filippi M,
    3. Rocca MA,
    4. Ciccarelli O, et al

    ; MAGNIMS Study Group. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol 2016;15:292–303 doi:10.1016/S1474-4422(15)00393-2 pmid:26822746

    CrossRefPubMed
15. 15.↵
    2. Wardlaw JM,
    3. Smith EE,
    4. Biessels GJ, et al

    ; STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013;12:822–38 doi:10.1016/S1474-4422(13)70124-8 pmid:23867200

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Rennebohm R,
    3. Susac JO,
    4. Egan RA, et al

    . Susac's syndrome: update. J Neurol Sci 2010;299:86–91 doi:10.1016/j.jns.2010.08.032 pmid:20855088

    CrossRefPubMed
17. 17.↵
    R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/. Accessed December 18, 2018.
18. 18.↵
    2. Mamourian AC,
    3. Hoopes PJ,
    4. Lewis LD

    . Visualization of intravenously administered contrast material in the CSF on fluid-attenuated inversion-recovery MR images: an in vitro and animal-model investigation. AJNR Am J Neuroradiol 2000;21:105–11 pmid:10669233

    Abstract/FREE Full Text
19. 19.↵
    2. Mathews VP,
    3. Caldemeyer KS,
    4. Lowe MJ, et al

    . Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology 1999;211:257–63 doi:10.1148/radiology.211.1.r99mr25257 pmid:10189481

    CrossRefPubMed
20. 20.↵
    2. Zivadinov R,
    3. Ramasamy DP,
    4. Hagemeier J, et al

    . Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol 2018;39:642–47 doi:10.3174/ajnr.A5541 pmid:29439125

    Abstract/FREE Full Text
21. 21.↵
    2. Latour LL,
    3. Kang DW,
    4. Ezzeddine MA, et al

    . Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468–77 doi:10.1002/ana.20199 pmid:15389899

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Hamilton BE,
    3. Nesbit GM

    . Delayed CSF enhancement in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2008;29:456–57 doi:10.3174/ajnr.A0926 pmid:18184835

    Abstract/FREE Full Text
23. 23.↵
    2. Naul LG,
    3. Finkenstaedt M

    . Extensive cerebrospinal fluid enhancement with gadopentetate dimeglumine in a primitive neuroectodermal tumor. AJNR Am J Neuroradiol 1997;18:1709–11 pmid:9367319

    Abstract
24. 24.↵
    2. Salvarani C,
    3. Brown RD Jr.,
    4. Calamia KT, et al

    . Primary central nervous system vasculitis with prominent leptomeningeal enhancement: a subset with a benign outcome. Arthritis Rheum 2008;58:595–603 doi:10.1002/art.23300 pmid:18240248

    CrossRefPubMedWeb of Science
25. 25.↵
    2. Wengert O,
    3. Rothenfusser-Korber E,
    4. Vollrath B, et al

    . Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity. J Neurol Sci 2013;335:124–30 doi:10.1016/j.jns.2013.09.008 pmid:24071064

    CrossRefPubMed
26. 26.↵
    2. Absinta M,
    3. Cortese ICM,
    4. Vuolo L, et al

    . Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology 2017;88:1439–44 doi:10.1212/WNL.0000000000003820 pmid:28283598

    Abstract/FREE Full Text
27. 27.↵
    2. Absinta M,
    3. Vuolo L,
    4. Rao A, et al

    . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85:18–28 doi:10.1212/WNL.0000000000001587 pmid:25888557

    Abstract/FREE Full Text
28. 28.↵
    2. Zivadinov R,
    3. Uher T,
    4. Hagemeier J, et al

    . A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler 2016;22:1709–18 doi:10.1177/1352458516629769 pmid:26883943

    CrossRefPubMed
29. 29.↵
    2. Kim W,
    3. Lee JE,
    4. Kim SH, et al

    . Cerebral cortex involvement in neuromyelitis optica spectrum disorder. J Clin Neurol 2016;12:188–93 doi:10.3988/jcn.2016.12.2.188 pmid:26833983

    CrossRefPubMed
30. 30.↵
    2. White ML,
    3. Zhang Y,
    4. Smoker WRK

    . Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. AJNR Am J Neuroradiol 2004;25:706–13 pmid:15140708

    Abstract/FREE Full Text
31. 31.↵
    2. Hardy TA,
    3. O'Brien B,
    4. Gerbis N, et al

    . Brain histopathology in three cases of Susac's syndrome: implications for lesion pathogenesis and treatment. J Neurol Neurosurg Psychiatry 2015;86:582–84 doi:10.1136/jnnp-2014-308240 pmid:25168394

    FREE Full Text
32. 32.↵
    2. McLeod DS,
    3. Ying HS,
    4. McLeod CA, et al

    . Retinal and optic nerve head pathology in Susac's syndrome. Ophthalmology 2011;118:548–52 doi:10.1016/j.ophtha.2010.07.012 pmid:20920828

    CrossRefPubMedWeb of Science
33. 33.↵
    2. Magro CM,
    3. Poe JC,
    4. Lubow M, et al

    . Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol 2011;136:903–12 doi:10.1309/AJCPERI7LC4VNFYK pmid:22095376

    CrossRefPubMed
34. 34.↵
    2. Egan RA,
    3. Hills WL,
    4. Susac JO

    . Gass plaques and fluorescein leakage in Susac syndrome. J Neurol Sci 2010;299:97–100 doi:10.1016/j.jns.2010.08.043 pmid:20880549

    CrossRefPubMed
35. 35.↵
    2. Garg N,
    3. Reddel SW,
    4. Miller DH, et al

    . The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases. J Neurol Neurosurg Psychiatry 2015;86:1374–82 doi:10.1136/jnnp-2014-309649 pmid:25857658

    Abstract/FREE Full Text
36. 36.↵
    2. Barkhof F,
    3. Filippi M,
    4. Miller DH, et al

    . Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain J Neurol 1997;120(Pt 11):2059–69 doi:10.1093/brain/120.11.2059 pmid:9397021

    CrossRefPubMedWeb of Science
37. 37.↵
    2. Paty DW,
    3. Li DK

    . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial—UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662–67 doi:10.1212/WNL.43.4.662 pmid:8469319

    Abstract/FREE Full Text
38. 38.↵
    2. Eisele P,
    3. Griebe M,
    4. Szabo K, et al

    . Investigation of leptomeningeal enhancement in MS: a postcontrast FLAIR MRI study. Neurology 2015;84:770–75 doi:10.1212/WNL.0000000000001286 pmid:25616480

    CrossRefPubMed